SOLVAY
23.9.2020 09:02:08 CEST | Business Wire | Press release
Solvay has won another patent infringement case in Germany against Neo Chemicals & Oxides Ltd.. In a judgment released on September 3, 2020, the Düsseldorf Regional Court concluded that Neo’s commercialization of certain Cerium/Zirconium based mixed oxides had infringed Solvay’s patent EP 1527018. The infringement judgment is still subject to Neo’s right to appeal, but enforceable immediately under the condition of the provision of a security while the European Patent Office has confirmed the validity of the patent in two instances.
The Court ordered Neo to stop the infringement, meaning that Neo must not commercialize its products covered by the Solvay patent in Germany any longer. Neo has also been ordered to recall the infringing products which are still kept by its customers. Solvay has taken steps to enforce the judgment.
Neo was previously held liable for numerous violations of Solvay’s patents in the rare earth field, including unappealable judgments handed down by superior courts in Germany and the UK. The decision just made by the Düsseldorf Court also shows that Neo’s current infringing activities expose customers and OEMs to compliance and supply chain risks.
The Court held that Neo had also infringed the catalyst claims of the patent by providing the infringing mixed oxides to customers who use them to make catalysts for automotive exhaust gas depollution. According to the judgment, these catalysts are also infringing the patent. This implies that the import of such catalysts into Germany would also infringe the patent.
Respect for Intellectual Property Rights is essential for free, healthy competition and to promote further innovation. Solvay will continue to take vigorous action to enforce its rights against infringers.
Rare earth oxides are key ingredients (or ‘raw materials’) in automotive catalysts that abate noxious gases from engine exhaust. Ever stricter air quality standards require increasingly complex formulations of rare earth oxides that are the result of extensive research and innovation programs. Solvay’s OPtalys® and Actalys® product ranges offer tailored solutions for all types of automotive catalysts and contribute significantly to cleaner mobility.
Neo is an indirect wholly-owned subsidiary of Neo Performance Materials Inc., which is headquartered in Toronto, Canada, traded on the Toronto Stock Exchange.
About Solvay
Solvay is a science company whose technologies bring benefits to many aspects of daily life. With more than 24,100 employees in 64 countries, Solvay bonds people, ideas and elements to reinvent progress. The Group seeks to create sustainable shared value for all, notably through its Solvay One Planet plan crafted around three pillars: protecting the climate, preserving resources and fostering better life. The Group’s innovative solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices, health care applications, water and air purification systems. Founded in 1863, Solvay today ranks among the world’s top three companies for the vast majority of its activities and delivered net sales of €10.2 billion in 2019. Solvay is listed on Euronext Brussels (SOLB) and Paris and in the United States, where its shares (SOLVY) are traded through a Level I ADR program. Learn more at www.solvay.com .
Follow us on Twitter @SolvayGroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005100/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
